Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 18, 2015; 7(26): 2676-2680
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2676
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2676
Hepatitis C virus: A global view
Amal Ahmed Mohamed, Biochemistry Department, National Hepatology and Tropical Medicine Institute, Cairo 11796, Egypt
Tamer A Elbedewy, Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31111, Egypt
Magdy El-Serafy, Tropical Department, National Hepatology and Tropical Medicine Institute; Cairo 11796, Egypt
Naglaa El-Toukhy, Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University, Banha 13511, Egypt
Wesam Ahmed, Zaniab Ali El Din, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
Author contributions: All authors contributed equally to this work.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Amal Ahmed Mohamed, Consultant of Biochemistry and Molecular Biology, Biochemistry Department, National Hepatology and Tropical Medicine Institute, Fom El-Khalig, Cairo 11796, Egypt. amalahmedhcp@yahoo.com
Telephone: +20-12-24847367
Received: September 9, 2014
Peer-review started: September 9, 2014
First decision: September 28, 2014
Revised: July 29, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Peer-review started: September 9, 2014
First decision: September 28, 2014
Revised: July 29, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Core Tip
Core tip: Peginterferon is responsible for many side effects. Direct-acting antiviral drugs represent a breakthrough in hepatitis C virus (HCV) therapy. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens. The next few years are expected to introduce more new drugs in the market of HCV therapy with complete elimination of pegylated interferon and ribavirin combination therapy.